市场调查报告书
商品编码
1471327
小分子原料药市场:按类型、产品、应用分类 - 2024-2030 年全球预测Small-Molecule APIs Market by Type (Biological, Synthetic), Production (Contract Manufacturing, In-House Manufacturing), Application - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年小分子原料药市场规模为1,843.2亿美元,预估2024年将达1,973.5亿美元,2030年将达3,011.9亿美元,复合年增长率为7.26%。
小分子活性药物成分是低分子量的有机化合物,通常小于 900 道尔顿。这些分子是药物中的活性成分,在给予患者时负责引发预期的治疗效果。小分子原料药由于尺寸小、结构简单,可以轻鬆地跨细胞膜扩散,这使得它们在靶向细胞内位点时特别有效。癌症、心血管疾病和感染疾病等慢性疾病的增加促进了市场的成长。药物开发週期的加速和全球学名药的普及正在推动小分子原料药的使用。然而,与药物开发相关的高成本和严格的监管标准限制了市场的成长。此外,接触活性药物成分对健康的影响正在阻碍市场成长。然而,将生产外包到具有成本效益的地点、开发复杂的合成方法以及在药物发现中利用人工智慧等策略可能会改变这个充满机会的行业的游戏规则。由于学名药的迅速普及和受託製造的扩张,有进一步的成长机会。
主要市场统计 | |
---|---|
基准年[2023] | 1843.2亿美元 |
预测年份 [2024] | 1973.5亿美元 |
预测年份 [2030] | 3011.9亿美元 |
复合年增长率(%) | 7.26% |
减少类型副作用增加对生物主题的倾向
生物来源小分子原料药来自或含有生物成分。这些 API 通常透过生物技术方法生产,例如重组 DNA 技术、受控基因表现、抗体技术和发酵製程。与合成原料药相比,生物原料药通常在结构上更加复杂,并且可以提供独特的治疗优势,例如更高的特异性和更少的副作用。合成小分子原料药是透过各种化学合成过程化学製造的。由于相对容易製造、扩充性以及药物开发中化学合成的丰富历史,该领域在小分子原料药市场占据主导地位。与生物原料药相比,合成原料原料药的生产量更大,成本更低。合成原料原料药涵盖广泛的学名药和非处方药,对于治疗许多疾病至关重要。
增加内部製造以确保生产品质标准
契约製造组织(CMO)在小分子原料药市场中发挥着至关重要的作用。 CMO 为出于各种原因希望委託製造的製药公司提供製造服务,这些原因包括节省成本、缺乏内部设备或需要专业知识。契约製造具有更大的灵活性,有助于管理与小分子原料药製造相关的复杂问题,例如法规遵循和品管。内部生产是指製药公司持有自己的低分子原料药生产设施。该细分市场包括拥有广泛资源和基础设施的大型製药公司,能够支持从原料药合成到最终产品配方的整个药品製造流程。内部製造可以更好地控制製造过程,有可能增加製造和研发的整合,并在智慧财产权保护和供应链管理方面提供策略优势。
应用:肿瘤学领域的不断进步将提高小分子原料药的利用率。
用于治疗CVD的小分子药物包括抗高血压药物、抗凝血药物和降胆固醇药物。全球心臟病、高血压和中风的高盛行率推动了对这些原料药的需求,因此需要强大的心血管治疗产品线。由于全球 1 型和 2 型糖尿病盛行率不断增加,与糖尿病相关的原料药正在扩大。胰岛素增敏剂、磺酰尿素和 SGLT2 抑制剂等小型分子药物对于控制血糖值和预防糖尿病相关併发症至关重要。免疫性疾病包括自体免疫疾病、过敏等多种疾病。用于治疗这些疾病的小分子原料药包括免疫抑制剂、发炎剂和抗组织胺药物。肿瘤学是小分子原料药市场最重要且发展最快的领域之一。对有效癌症治疗的迫切需求推动了对肿瘤原料药的需求。小分子化疗、激酶抑制剂和荷尔蒙疗法是癌症治疗方法中使用的原料药。
区域洞察
美洲地区的特点是强大的製药业、先进的医疗基础设施以及对研发的高度重视。领先的製药公司和尖端生物技术公司的存在促进了对小分子原料药的高需求。美国食品药物管理局(FDA) 的严格监管确保了高品质标准,使美国地区成为原料药生产的一个有吸引力的地点。欧洲是小分子原料药的主要市场,并拥有成熟的製药业。欧洲国家以其对药品创新和生产的重大贡献而闻名。欧洲药品管理局(EMA)在监管原料药的品质和安全方面发挥重要作用,创造了高度监管的市场环境。此外,欧洲的战略贸易协定和对学名药的强烈关注正在推动该地区对小分子原料药的需求。在中东和非洲地区,文明病的盛行率不断上升以及政府改善医疗保健系统的倡议是刺激市场成长的因素。在中国、日本和印度等新兴国家的推动下,亚太地区小分子 API 市场正在快速成长。由于较低的生产成本、熟练的劳动力以及医疗基础设施投资的增加,这些国家正在成为原料药製造的全球中心。该地区人口众多,慢性病盛行,也导致药品和原料药的需求增加。
FPNV定位矩阵
FPNV定位矩阵对于评估小分子原料药市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对小分子原料药市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4.竞争力评估与资讯:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1.小分子原料药市场规模及预测是多少?
2.小分子原料药市场预测期间需要考虑投资的产品、细分市场、应用和领域有哪些?
3.小分子原料药市场的技术趋势与法规结构是什么?
4.小分子原料药市场主要厂商的市场占有率是多少?
5.进入小分子原料药市场合适的型态与策略手段是什么?
[185 Pages Report] The Small-Molecule APIs Market size was estimated at USD 184.32 billion in 2023 and expected to reach USD 197.35 billion in 2024, at a CAGR 7.26% to reach USD 301.19 billion by 2030.
Small-molecule Active Pharmaceutical Ingredients are organic compounds with a low molecular weight, typically below 900 daltons. These molecules are the active components in pharmaceuticals that are responsible for eliciting the intended therapeutic effect when administered to patients. Small-molecule APIs can easily diffuse across cell membranes because of their small size and simple structure, making them particularly effective in targeting intracellular sites. Growing chronic disease prevalence, including cancer, cardiovascular, and infectious diseases, contributes to the market growth. Accelerated drug development cycles and rising adoption of generic drugs across the globe boost the utilization of small-molecule API. However, high costs and stringent regulatory standards associated with drug development limit the growth of the market. In addition, the health effects of exposure to active pharmaceutical ingredients create hindrances to market growth. However, strategies such as outsourcing production to cost-effective locations, developing sophisticated synthesis methods, and leveraging AI in drug discovery can be potential game-changers for an industry ripe with opportunity. Further growth opportunities exist due to the burgeoning generic drugs popularity and expanding contract manufacturing sectors.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 184.32 billion |
Estimated Year [2024] | USD 197.35 billion |
Forecast Year [2030] | USD 301.19 billion |
CAGR (%) | 7.26% |
Type: Growing inclination towards biological based small-molecule APIs due to its reduced side effects
Biological small-molecule APIs are derived from living organisms or contain components of living organisms. These APIs are typically produced through biotechnological methods, including recombinant DNA technology, controlled gene expression, antibody technologies, and fermentation processes. Biological APIs are often more complex in structure compared to their synthetic counterparts and may offer unique therapeutic benefits, such as high specificity and reduced side effects. Synthetic small-molecule APIs are chemically manufactured through various chemical synthesis processes. This segment dominates the small-molecule APIs market due to the relative ease of production, scalability, and the extensive history of chemical synthesis in drug development. Synthetic APIs can be produced in large quantities and at a lower cost compared to biological APIs. They encompass a wide range of drugs, including generics and over-the-counter medications, and are critical in treating a multitude of conditions.
Production: Increasing in-house small-molecule APIs manufacturing to ensure quality standards
Contract manufacturing organizations (CMOs) play a pivotal role in the small-molecule APIs market. They offer their manufacturing services to pharmaceutical companies that prefer to outsource production for various reasons, such as cost reduction, lack of in-house facilities, or the need for specialized expertise. Contract manufacturing allows for greater flexibility and can help companies manage the complexities associated with the production of small-molecule APIs, including regulatory compliance and quality control. In-house manufacturing refers to pharmaceutical companies that maintain their own production facilities for small-molecule APIs. This segment includes large pharmaceutical companies with extensive resources and infrastructure that can support the entire drug manufacturing process, from API synthesis to final product formulation. In-house manufacturing allows for greater control over the production process, potentially leading to better integration of manufacturing and R&D efforts, and can provide a strategic advantage in terms of protecting intellectual property and supply chain management.
Application: Ongoing advancements in oncology enhances the utilization of small-molecule APIs
Small-molecule drugs used in the treatment of CVDs include antihypertensives, anticoagulants, and cholesterol-lowering drugs, among others. The demand for these APIs is driven by the high global prevalence of heart disease, hypertension, and stroke, necessitating a robust pipeline of cardiovascular medications. Diabetes-related APIs are expanding due to the increasing incidence of Type 1 and Type 2 diabetes worldwide. Small-molecule drugs such as insulin sensitizers, sulfonylureas, and SGLT2 inhibitors are essential in managing blood glucose levels and preventing complications associated with diabetes. Immunological disorders encompass a wide range of conditions, including autoimmune diseases and allergies. Small-molecule APIs used in the treatment of these disorders include immunosuppressants, anti-inflammatory drugs, and antihistamines. Oncology is one of the most critical and rapidly evolving segments in the small-molecule APIs market. The demand for oncology APIs is driven by the urgent need for effective cancer treatments. Small-molecule chemotherapeutic agents, kinase inhibitors, and hormone therapies are among the APIs used in cancer treatment regimens.
Regional Insights
The American region is characterized by a robust pharmaceutical industry, advanced healthcare infrastructure, and a strong focus on research and development. The presence of major pharmaceutical companies, along with cutting-edge biotechnology firms, contributes to the high demand for small-molecule APIs. Stringent regulations by the U.S. Food and Drug Administration (FDA) ensure high-quality standards, making American regions an attractive location for API manufacturing. Europe stands as a key market for small-molecule APIs, with a well-established pharmaceutical sector. European countries are known for their significant contributions to pharmaceutical innovation and production. The European Medicines Agency (EMA) plays a crucial role in regulating API quality and safety, fostering a highly regulated market environment. Additionally, Europe's strategic trade agreements and a strong emphasis on generic drugs bolster the demand for small-molecule APIs in the region. The increasing incidence of lifestyle-related diseases and government initiatives to improve healthcare systems are factors that could stimulate market growth across the Middle East and Africa. The APAC region is witnessing rapid growth in the small-molecule API market, driven by emerging economies such as China, Japan, and India. These countries are becoming global hubs for API manufacturing due to lower production costs, skilled labor, and increasing investments in healthcare infrastructure. The region's large population base and growing prevalence of chronic diseases also contribute to the rising demand for pharmaceuticals and APIs.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Small-Molecule APIs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Small-Molecule APIs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Small-Molecule APIs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agilent Technologies, Inc., Alacrita Holdings Limited, Albemarle Corporation, Aspen Group, Astrazeneca PLC, Aurobindo Pharma Limited, Bachem Holding AG, Bio-Rad Laboratories, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Cambrex Corporation by Permira funds, Carlyle Group, Charles River Laboratories International, Inc., Deciphera Pharmaceuticals, Inc., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd,, Gilead Sciences, Inc, GlaxoSmithKline PLC, Koninklijke DSM N.V., Lonza Group AG, Merck KGaA, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Small-Molecule APIs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Small-Molecule APIs Market?
3. What are the technology trends and regulatory frameworks in the Small-Molecule APIs Market?
4. What is the market share of the leading vendors in the Small-Molecule APIs Market?
5. Which modes and strategic moves are suitable for entering the Small-Molecule APIs Market?